Advertisements


Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon.....»»

Category: earningsSource: benzingaApr 16th, 2018

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

14-day Study of PTI-801, Company's Third Generation Corrector, in CF Patients on Background Orkambi® Enrolling Ahead of Schedule; Results from All Three Cohorts Expected Q2'18 Company Announces Additional Study of PTI-428 in CF.....»»

Category: earningsSource: benzingaMar 14th, 2018

Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update

Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million Forms Strategic Bispecific Antibody Partnership with Alligator Bioscience Demonstrating Versatility of the ADAPTIR™ Technology Platform Advances Multiple AD.....»»

Category: earningsSource: benzingaMar 13th, 2018

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results

- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy -- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass., March .....»»

Category: earningsSource: benzingaMar 8th, 2018

Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a .....»»

Category: earningsSource: benzingaMar 7th, 2018

Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update

All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expe.....»»

Category: earningsSource: benzingaNov 7th, 2017

Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results

WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter .....»»

Category: earningsSource: benzingaNov 7th, 2017

Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:G.....»»

Category: earningsSource: benzingaAug 18th, 2017

Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today repor.....»»

Category: earningsSource: benzingaAug 14th, 2017

TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 201.....»»

Category: earningsSource: benzingaAug 9th, 2017

Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update

WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company, today provided a business updat.....»»

Category: earningsSource: benzingaAug 7th, 2017

Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights

- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), .....»»

Category: earningsSource: benzingaApr 3rd, 2018

Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update

Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in Stroke Expanded Intellectual Property Portfol.....»»

Category: earningsSource: benzingaApr 3rd, 2018

Net Element Reports Full-Year 2017 Financial Results and Provides Business Update

Net Element Reports Full-Year 2017 Financial Results and Provides Business Update.....»»

Category: earningsSource: benzingaApr 2nd, 2018

SANUWAVE Health Reports 2017 Financial Results and Provides a Business Update

SANUWAVE Health Reports 2017 Financial Results and Provides a Business Update.....»»

Category: earningsSource: benzingaMar 29th, 2018

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

 -- Initiated URIROX-1™, First Phase.....»»

Category: earningsSource: benzingaMar 27th, 2018

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it.....»»

Category: earningsSource: benzingaMar 19th, 2018

Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update

Company to host webcast and conference call on Tuesday, March 20, 2018 at 8 am ET Management to discuss recent data and progress on development plans WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. ("Eloxx") .....»»

Category: earningsSource: benzingaMar 19th, 2018

Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene th.....»»

Category: earningsSource: benzingaMar 16th, 2018

OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update

OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update.....»»

Category: earningsSource: benzingaMar 15th, 2018

Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update

Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update.....»»

Category: earningsSource: benzingaMar 15th, 2018